Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ACIU
STRONG SELLAC Immune SA · Healthcare · Switzerland · $299M · Avg Vol: $533K/d
COMPANY DESCRIPTION
AC Immune SA is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing precision medicines and diagnostics for neurodegenerative diseases, focusing on conditions like Alzheimer's and Parkinson's. The company leverages proprietary technology platforms like Morphomer and SupraAntigen to target misfolded proteins, a key pathological hallmark of these diseases. AC Immune's competitive edge is its specialized R&D in this complex field, aiming to bring innovative solutions to areas of high unmet medical need.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.9M | 18.3M | 33.7M | 4.4M | -3.2% | 4.6M | 44.8M | 108.4M | 395.6% |
| EPS | -1.05 | -0.79 | -0.63 | -0.86 | — | -0.82 | -0.59 | 0.61 | — |
| Shares | 83.6M | 99.2M | 100.4M | 101.7M | +21.7% | 101.8M | — | — | — |
| Debt | 3.5M | 4.3M | 6.7M | 5.6M | 17.5% | 5.3M | — | — | — |
| Equity | 208.8M | 198.4M | 138.7M | 55.4M | -35.7% | — | — | — | — |
| Op CF | -90.9M | -74.6M | 81.3M | -85.6M | — | — | — | — | — |
| Inv CF | 29.4M | 81.1M | -130.1M | 78.5M | — | — | — | — | — |
| Fin CF | -1.7M | 53.4M | -1.4M | -1.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ACIU are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ACIU | AC Immune SA(you) | $299M | 10 | STRONG SELL |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $290M | 24 | SELL |
| OCS | Oculis Holding AG | $672M | 7 | STRONG SELL |
| MOLN.SW | Molecular Partners AG | $147M | 22 | SELL |
| MLTX | MoonLake Immunotherapeutics | $1.6B | 18 | STRONG SELL |
| 0QNA.L | Basilea Pharmaceutica AG | $733M | 49 | HOLD |
| PHVS | Pharvaris N.V. | $2.4B | 26 | SELL |
| CRSP | CRISPR Therapeutics AG | $4.6B | 14 | STRONG SELL |
| IDIA.SW | Idorsia Ltd | $2.2B | 33 | SELL |
| BANB.SW | Bachem Holding AG | $6.7B | 52 | HOLD |
Peer medians: ROE 12.1% · P/E 25.2x · Gross margin 55.8%